Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
SenzaGen AB
SenzaGen Group is a leading company in in vitro science and testing, specializing in non-animal test methods to replace traditional animal testing. Their proprietary GARD® assays use genomics and…
SenzaGen AB
SenzaGen Group is a leading company in in vitro science and testing, specializing in non-animal test methods to replace traditional animal testing. Their proprietary GARD® assays use genomics and…
TL;DR
Founded: 2010
Headquarters: Lund, Sweden (Medicon Village)
Core technology: GARD® genomics + machine learning assays for sensitization testing
Industry / focus: Non-animal in vitro testing, immunotoxicology and safety assessment
Public listing: Listed on Nasdaq Stockholm (ticker: SENZA)
Company Overview
Problem Domain
Replace animal-based sensitization and immunotoxicology testing with human-relevant in vitro methods to improve safety assessment and regulatory compliance.
Founded
2010
Industry
Biotechnology
Funding Track Record
2551595
Recorded grant round closed Mar 1, 2017; company press releases document an EU Horizon-related grant (~€2.4M) announced in 2016.
≈17.5 MSEK
Directed rights issue to institutional investor reported by the company.
Investor Signal
“Public company with grant financing history and institutional investor participation (Eiffel Investment Group) in a directed share issue.”